These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 33953374)
1. Use of teprotumumab in thyroid eye disease. Greenhill C Nat Rev Endocrinol; 2021 Jul; 17(7):383. PubMed ID: 33953374 [No Abstract] [Full Text] [Related]
2. Teprotumumab: First Approval. Markham A Drugs; 2020 Apr; 80(5):509-512. PubMed ID: 32157641 [TBL] [Abstract][Full Text] [Related]
3. Teprotumumab for the treatment of thyroid eye disease. Ju Y; Yang J Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005 [TBL] [Abstract][Full Text] [Related]
4. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501 [TBL] [Abstract][Full Text] [Related]
5. Teprotumumab for Asymmetric Thyroid Eye Disease. Ugradar S; Wang Y; Douglas R Ophthalmology; 2021 Oct; 128(10):1416. PubMed ID: 34556309 [No Abstract] [Full Text] [Related]
6. Teprotumumab (Tepezza) for thyroid eye disease. Med Lett Drugs Ther; 2021 May; 63(1625):87-88. PubMed ID: 34101720 [No Abstract] [Full Text] [Related]
8. Teprotumumab for Inactive Thyroid Eye Disease? The Jury Is Still Out. Dosiou C J Clin Endocrinol Metab; 2024 Aug; 109(9):e1802-e1803. PubMed ID: 38279938 [No Abstract] [Full Text] [Related]
9. Teprotumumab for Thyroid Eye Disease. Hwang CJ; Eftekhari K Int Ophthalmol Clin; 2020; 60(2):47-55. PubMed ID: 32205652 [No Abstract] [Full Text] [Related]
10. Teprotumumab for Optic Neuropathy in Thyroid Eye Disease. Slentz DH; Smith TJ; Kim DS; Joseph SS JAMA Ophthalmol; 2021 Feb; 139(2):244-247. PubMed ID: 33270090 [No Abstract] [Full Text] [Related]
11. Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment. Ali F; Chorsiya A; Anjum V; Ali A Int Ophthalmol; 2021 Apr; 41(4):1549-1561. PubMed ID: 33481154 [TBL] [Abstract][Full Text] [Related]
12. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy. Smith TJ Front Endocrinol (Lausanne); 2020; 11():610337. PubMed ID: 33391187 [TBL] [Abstract][Full Text] [Related]
13. [Teprotumumab for the treatment of thyroid eye disease: The Holy grail, really?]. Martel A J Fr Ophtalmol; 2023 Jun; 46(6):567-570. PubMed ID: 37068976 [No Abstract] [Full Text] [Related]
14. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists. Chern A; Dagi Glass LR; Gudis DA Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112 [TBL] [Abstract][Full Text] [Related]
15. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition. Smith TJ J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069 [TBL] [Abstract][Full Text] [Related]
16. Teprotumumab: The First Approved Biologic for Thyroid Eye Disease. Hwang CJ; Eftekhari K Int Ophthalmol Clin; 2021 Apr; 61(2):53-61. PubMed ID: 33743528 [No Abstract] [Full Text] [Related]
17. Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears? Bartalena L; Marinò M; Marcocci C; Tanda ML J Endocrinol Invest; 2022 Jul; 45(7):1455-1457. PubMed ID: 35403994 [No Abstract] [Full Text] [Related]
18. The role of teprotumumab in chronic, clinically active thyroid eye disease. Yu CY; Simmons BA; Pham CM; Shriver EM Eye (Lond); 2022 Jul; 36(7):1500-1501. PubMed ID: 34983925 [No Abstract] [Full Text] [Related]
19. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy. Slentz DH; Nelson CC; Smith TJ Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706 [TBL] [Abstract][Full Text] [Related]
20. The knowns and unknowns of teprotumumab for thyroid eye disease. Bednarczuk T; Pearce SH Lancet Diabetes Endocrinol; 2021 Jun; 9(6):323-325. PubMed ID: 33865499 [No Abstract] [Full Text] [Related] [Next] [New Search]